The findings suggest that patients with tumor progression exhibit significantly elevated FAP levels compared to those without recurrent glioma, thereby highlighting the potential of blood tumor markers for glioma as a sensitive tool for early diagnosis. The gene discussed is FAP; the disease is central nervous system cancer.